Optinose to Present at the Needham Virtual Healthcare ConferenceGlobe Newswire • 19 days ago
YARDLEY, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Share to Feed
OptiNose, Inc. (NASDAQ:OPTN Get Free Report) CEO Ramy A. Mahmoud sold 19,198 shares of the stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price...
OptiNose (NASDAQ:OPTN Free Report) had its price target raised by Lake Street Capital from $3.00 to $4.00 in a report published on Monday, Benzinga reports. The brokerage currently has a buy...
OptiNose (NASDAQ:OPTN Free Report) had its price target raised by Lake Street Capital from $3.00 to $4.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Matthew Caufield, an analyst from H.C. Wainwright, reiterated the Buy rating on Optinose (OPTN Research Report). The associated price target is...
OptiNose granted FDA nod to expand labeling for sinusitis therapy...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps Clinical...